L & S Advisors’s BeOne Medicines Ltd ONC Stock Holding History

L & S Advisors’s Portfolio ONC Stock Details ONC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-1,000	Closed	-$286K	–	369
2020 Q3	$286K	Buy	+1,000	New	+$235K	0.04%	256

Other funds holding ONC

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

L & S Advisors's ONC Position: Q4 2020 in Review

L & S Advisors sold out of BeOne Medicines Ltd (ONC) in Q4 2020, closing a stake of 1,000 shares — an estimated $286K sold.

L & S Advisors first reported a position in ONC in Q3 2020 and held it in 1 quarter. The position peaked at $286K in Q3 2020. 247 funds tracked by Wall St. Rank hold ONC as of Q4 2020.

L & S Advisors reported no remaining BeOne Medicines Ltd position as of Q4 2020 after selling out during the quarter.
L & S Advisors sold 1,000 BeOne Medicines Ltd shares in Q4 2020, an estimated $286K.
L & S Advisors first reported a position in BeOne Medicines Ltd in Q3 2020 and held it in 1 quarter.
L & S Advisors's BeOne Medicines Ltd position peaked at $286K in Q3 2020.
247 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q4 2020.

Based on L & S Advisors's 13F filing for Q4 2020, filed 16 Feb 2021.